CardioComm Solutions, Inc. Logo

CardioComm Solutions, Inc.

EKGGF

(1.5)
Stock Price

0,01 USD

-39.41% ROA

45.13% ROE

-15.29x PER

Market Cap.

2.755.447,55 USD

-87.02% DER

0% Yield

-35.51% NPM

CardioComm Solutions, Inc. Stock Analysis

CardioComm Solutions, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

CardioComm Solutions, Inc. Fundamental Stock Analysis
# Analysis Rating
1 ROE

ROE surpassing expectations (28.01%) highlights strong profitability and efficient use of shareholders' equity, making it an appealing investment prospect.

2 PBV

With a remarkably low PBV ratio (-5.29x), the stock offers substantial upside potential at a bargain price.

3 DER

The stock has a low debt to equity ratio (-105%), which means it has a small amount of debt compared to the ownership it holds

4 ROA

The stock's ROA (-30.65%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

5 Revenue Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

6 Net Profit Growth

Despite the passage of five years, this company's net profit has not shown any improvement, highlighting a lack of growth and making it a less appealing investment prospect.

7 Assets Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

8 Graham Number

The Graham number analysis indicates that this company's stock price is likely overpriced, raising concerns about its investment potential.

9 Dividend Growth

Investors should note the company's stagnant dividend growth over the past three years, indicating limited profitability and potentially diminishing returns.

10 Dividend

Investors should be cautious as the company hasn't distributed dividends in the last three years, possibly indicating financial challenges.

11 Buffet Intrinsic Value

The company's stock presents a potential concern as it appears overvalued (0) by Warren Buffett's formula, indicating that its market price exceeds its estimated intrinsic value.

CardioComm Solutions, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

CardioComm Solutions, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Sell
3 RSI Hold
4 Stoch RSI Buy

CardioComm Solutions, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

CardioComm Solutions, Inc. Revenue
Year Revenue Growth
1997 198.012
1998 78.190 -153.24%
1999 38.320 -104.04%
2000 205.043 81.31%
2001 386.962 47.01%
2002 1.001.116 61.35%
2003 1.718.476 41.74%
2004 2.746.251 37.42%
2005 1.016.293 -170.22%
2006 1.761.871 42.32%
2007 960.395 -83.45%
2008 724.918 -32.48%
2009 1.300.921 44.28%
2010 1.847.035 29.57%
2011 2.277.136 18.89%
2012 1.605.690 -41.82%
2013 1.695.163 5.28%
2014 1.504.994 -12.64%
2015 1.725.372 12.77%
2016 1.557.550 -10.77%
2017 1.740.269 10.5%
2018 1.075.564 -61.8%
2019 874.888 -22.94%
2020 834.785 -4.8%
2021 682.511 -22.31%
2022 995.814 31.46%
2023 1.007.332 1.14%
2023 876.414 -14.94%
2024 396.808 -120.87%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

CardioComm Solutions, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
1997 1.137.173
1998 1.118.526 -1.67%
1999 270.505 -313.5%
2000 30.625 -783.28%
2001 42.523 27.98%
2002 606.135 92.98%
2003 737.439 17.81%
2004 1.127.754 34.61%
2005 1.075.302 -4.88%
2006 1.011.619 -6.3%
2007 651.111 -55.37%
2008 385.384 -68.95%
2009 431.797 10.75%
2010 669.172 35.47%
2011 796.866 16.02%
2012 1.871.360 57.42%
2013 950.888 -96.8%
2014 374.215 -154.1%
2015 108.445 -245.07%
2016 81.603 -32.89%
2017 87.650 6.9%
2018 94.875 7.62%
2019 24.562 -286.27%
2020 0 0%
2021 11.144 100%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

CardioComm Solutions, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
1997 1.819.681
1998 1.027.094 -77.17%
1999 668.359 -53.67%
2000 1.908.813 64.99%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 1.151.898 100%
2017 1.270.549 9.34%
2018 1.160.525 -9.48%
2019 1.000.452 -16%
2020 758.985 -31.81%
2021 806.219 5.86%
2022 623.993 -29.2%
2023 844.352 26.1%
2023 809.875 -4.26%
2024 689.104 -17.53%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

CardioComm Solutions, Inc. EBITDA
Year EBITDA Growth
1997 -2.880.772
1998 -2.199.946 -30.95%
1999 -918.153 -139.61%
2000 -1.854.822 50.5%
2001 -2.455.787 24.47%
2002 -1.241.489 -97.81%
2003 -900.541 -37.86%
2004 -300.868 -199.31%
2005 -1.486.773 79.76%
2006 -610.136 -143.68%
2007 -1.417.715 56.96%
2008 -1.595.908 11.17%
2009 -995.432 -60.32%
2010 -251.376 -295.99%
2011 -635.267 60.43%
2012 -3.273.923 80.6%
2013 -1.686.669 -94.11%
2014 -896.649 -88.11%
2015 -595.934 -50.46%
2016 27.158 2294.32%
2017 164.772 83.52%
2018 -493.775 133.37%
2019 -381.102 -29.57%
2020 28.307 1446.32%
2021 82.928 65.87%
2022 29.807 -178.22%
2023 -52.348 156.94%
2023 -183.090 71.41%
2024 -403.200 54.59%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

CardioComm Solutions, Inc. Gross Profit
Year Gross Profit Growth
1997 173.244
1998 76.063 -127.76%
1999 36.886 -106.21%
2000 175.382 78.97%
2001 307.029 42.88%
2002 1.001.116 69.33%
2003 1.718.476 41.74%
2004 2.746.251 37.42%
2005 1.016.293 -170.22%
2006 1.761.871 42.32%
2007 960.395 -83.45%
2008 -363.677 364.08%
2009 -386.368 5.87%
2010 475.051 181.33%
2011 212.589 -123.46%
2012 -115.998 283.27%
2013 -104.936 -10.54%
2014 -95.448 -9.94%
2015 74.875 227.48%
2016 441.620 83.05%
2017 1.541.235 71.35%
2018 778.232 -98.04%
2019 693.233 -12.26%
2020 734.596 5.63%
2021 637.446 -15.24%
2022 740.385 13.9%
2023 968.912 23.59%
2023 165.178 -486.59%
2024 -37.972 535%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

CardioComm Solutions, Inc. Net Profit
Year Net Profit Growth
1997 -3.129.324
1998 -2.514.603 -24.45%
1999 -1.020.765 -146.34%
2000 -1.905.660 46.44%
2001 -2.502.835 23.86%
2002 -1.332.535 -87.83%
2003 -989.779 -34.63%
2004 -403.784 -145.13%
2005 -1.541.518 73.81%
2006 -625.128 -146.59%
2007 -2.176.311 71.28%
2008 -1.584.621 -37.34%
2009 -1.080.661 -46.63%
2010 -314.148 -244%
2011 -669.656 53.09%
2012 -3.342.457 79.97%
2013 -1.702.764 -96.3%
2014 -954.899 -78.32%
2015 -599.748 -59.22%
2016 -23.057 -2501.15%
2017 39.609 158.21%
2018 -577.063 106.86%
2019 -1.062.108 45.67%
2020 -63.606 -1569.82%
2021 283 22575.62%
2022 -2.455 111.53%
2023 -119.852 97.95%
2023 -97.326 -23.14%
2024 -279.496 65.18%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

CardioComm Solutions, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1997 -4
1998 -3 -50%
1999 -1 0%
2000 -1 0%
2001 -1 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

CardioComm Solutions, Inc. Free Cashflow
Year Free Cashflow Growth
1997 -3.492.636
1998 -1.975.806 -76.77%
1999 -974.364 -102.78%
2000 -1.937.326 49.71%
2001 -1.955.473 0.93%
2002 -1.316.747 -48.51%
2003 -855.535 -53.91%
2004 -632.437 -35.28%
2005 -799.709 20.92%
2006 -132.761 -502.37%
2007 -1.947.844 93.18%
2008 -1.534.748 -26.92%
2009 -632.176 -142.77%
2010 -610.960 -3.47%
2011 -115.126 -430.69%
2012 -3.501.339 96.71%
2013 -1.007.898 -247.39%
2014 -485.725 -107.5%
2015 -301.889 -60.9%
2016 -152.511 -97.95%
2017 -295.048 48.31%
2018 -208.742 -41.35%
2019 -70.382 -196.58%
2020 23.403 400.74%
2021 -123.429 118.96%
2022 44.328 378.44%
2023 -167.352 126.49%
2023 -56.091 -198.36%
2024 -62.614 10.42%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

CardioComm Solutions, Inc. Operating Cashflow
Year Operating Cashflow Growth
1997 -3.314.478
1998 -1.958.339 -69.25%
1999 -955.689 -104.91%
2000 -1.740.961 45.11%
2001 -1.900.072 8.37%
2002 -1.269.448 -49.68%
2003 -821.062 -54.61%
2004 -593.578 -38.32%
2005 -795.240 25.36%
2006 -124.680 -537.82%
2007 -1.933.573 93.55%
2008 -1.455.376 -32.86%
2009 -596.141 -144.13%
2010 -582.445 -2.35%
2011 -89.667 -549.56%
2012 -3.460.201 97.41%
2013 -942.441 -267.15%
2014 -462.749 -103.66%
2015 -294.495 -57.13%
2016 -149.930 -96.42%
2017 -291.704 48.6%
2018 -192.532 -51.51%
2019 -61.886 -211.11%
2020 39.401 257.07%
2021 -120.798 132.62%
2022 54.516 321.58%
2023 -167.352 132.58%
2023 -54.067 -209.53%
2024 -62.614 13.65%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

CardioComm Solutions, Inc. Capital Expenditure
Year Capital Expenditure Growth
1997 178.158
1998 17.467 -919.97%
1999 18.675 6.47%
2000 196.365 90.49%
2001 55.401 -254.44%
2002 47.299 -17.13%
2003 34.473 -37.21%
2004 38.859 11.29%
2005 4.469 -769.52%
2006 8.081 44.7%
2007 14.271 43.37%
2008 79.372 82.02%
2009 36.035 -120.26%
2010 28.515 -26.37%
2011 25.459 -12%
2012 41.138 38.11%
2013 65.457 37.15%
2014 22.976 -184.89%
2015 7.394 -210.74%
2016 2.581 -186.48%
2017 3.344 22.82%
2018 16.210 79.37%
2019 8.496 -90.8%
2020 15.998 46.89%
2021 2.631 -508.06%
2022 10.188 74.18%
2023 0 0%
2023 2.024 100%
2024 0 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

CardioComm Solutions, Inc. Equity
Year Equity Growth
1997 1.938.019
1998 211.852 -814.8%
1999 316.747 33.12%
2000 1.072.082 70.45%
2001 -1.210.063 188.6%
2002 -777.098 -55.72%
2003 -458.527 -69.48%
2004 -460.611 0.45%
2005 -1.993.552 76.89%
2006 -2.310.172 13.71%
2007 -994.792 -132.23%
2008 -238.686 -316.78%
2009 -687.897 65.3%
2010 37.281 1945.17%
2011 -176.938 121.07%
2012 523.191 133.82%
2013 -339.454 254.13%
2014 -595.834 43.03%
2015 -687.894 13.38%
2016 -7.741 -8786.37%
2017 489.316 101.58%
2018 -68.413 815.24%
2019 -895.809 92.36%
2020 -670.318 -33.64%
2021 -423.375 -58.33%
2022 -407.324 -3.94%
2023 -417.913 2.53%
2023 -504.650 17.19%
2024 -526.681 4.18%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

CardioComm Solutions, Inc. Assets
Year Assets Growth
1997 2.107.985
1998 278.514 -656.87%
1999 559.168 50.19%
2000 1.349.999 58.58%
2001 461.840 -192.31%
2002 415.829 -11.06%
2003 929.995 55.29%
2004 686.209 -35.53%
2005 202.963 -238.1%
2006 427.395 52.51%
2007 437.177 2.24%
2008 582.875 25%
2009 459.816 -26.76%
2010 477.647 3.73%
2011 798.291 40.17%
2012 1.021.526 21.85%
2013 979.828 -4.26%
2014 1.048.042 6.51%
2015 1.047.676 -0.03%
2016 1.149.768 8.88%
2017 1.539.413 25.31%
2018 1.089.796 -41.26%
2019 323.384 -237%
2020 360.617 10.32%
2021 486.472 25.87%
2022 279.724 -73.91%
2023 380.639 26.51%
2023 341.997 -11.3%
2024 357.992 4.47%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

CardioComm Solutions, Inc. Liabilities
Year Liabilities Growth
1997 169.966
1998 66.662 -154.97%
1999 242.421 72.5%
2000 277.917 12.77%
2001 1.671.903 83.38%
2002 1.192.927 -40.15%
2003 1.388.522 14.09%
2004 1.146.820 -21.08%
2005 2.196.515 47.79%
2006 2.737.567 19.76%
2007 1.431.969 -91.18%
2008 821.561 -74.3%
2009 1.147.713 28.42%
2010 440.366 -160.63%
2011 975.229 54.84%
2012 498.335 -95.7%
2013 1.319.282 62.23%
2014 1.643.876 19.75%
2015 1.735.570 5.28%
2016 1.157.509 -49.94%
2017 1.050.097 -10.23%
2018 1.158.209 9.33%
2019 1.219.193 5%
2020 1.030.935 -18.26%
2021 909.847 -13.31%
2022 687.048 -32.43%
2023 798.552 13.96%
2023 846.647 5.68%
2024 884.673 4.3%

CardioComm Solutions, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0
Net Income per Share
-0
Price to Earning Ratio
-15.29x
Price To Sales Ratio
4.28x
POCF Ratio
-12.89
PFCF Ratio
-16.27
Price to Book Ratio
-4.1
EV to Sales
4.98
EV Over EBITDA
-9.68
EV to Operating CashFlow
-19.15
EV to FreeCashFlow
-18.92
Earnings Yield
-0.07
FreeCashFlow Yield
-0.06
Market Cap
0,00 Bil.
Enterprise Value
0,00 Bil.
Graham Number
0.01
Graham NetNet
-0

Income Statement Metrics

Net Income per Share
-0
Income Quality
1.19
ROE
0.3
Return On Assets
-0.57
Return On Capital Employed
2.23
Net Income per EBT
1
EBT Per Ebit
0.56
Ebit per Revenue
-0.64
Effective Tax Rate
0.19

Margins

Sales, General, & Administrative to Revenue
1.34
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.42
Operating Profit Margin
-0.64
Pretax Profit Margin
-0.36
Net Profit Margin
-0.36

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0
Free CashFlow per Share
-0
Capex to Operating CashFlow
-0.01
Capex to Revenue
0
Capex to Depreciation
0.08
Return on Invested Capital
4.28
Return on Tangible Assets
-0.39
Days Sales Outstanding
127.18
Days Payables Outstanding
169.44
Days of Inventory on Hand
35.44
Receivables Turnover
2.87
Payables Turnover
2.15
Inventory Turnover
10.3
Capex per Share
0

Balance Sheet

Cash per Share
0,00
Book Value per Share
0,00
Tangible Book Value per Share
-0
Shareholders Equity per Share
-0
Interest Debt per Share
0
Debt to Equity
-0.87
Debt to Assets
1.28
Net Debt to EBITDA
-1.36
Current Ratio
0.34
Tangible Asset Value
0,00 Bil.
Net Current Asset Value
0,00 Bil.
Invested Capital
-487791
Working Capital
0,00 Bil.
Intangibles to Total Assets
0
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
41481
Debt to Market Cap
0.17

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

CardioComm Solutions, Inc. Dividends
Year Dividends Growth

CardioComm Solutions, Inc. Profile

About CardioComm Solutions, Inc.

CardioComm Solutions, Inc. develops advanced software and hardware products, and core laboratory reading services related to electrocardiogram (ECG) and ambulatory arrhythmia monitoring systems for medical and consumer markets worldwide. The company's technology is used in a range of products for the recording, transmission, viewing, analyzing, reporting, and storage of ECGs for arrhythmia screening, diagnosis, and management of cardiac patients. Its proprietary device connectivity and ECG management technologies are used in medical, consumer, clinical research, and telemedicine solutions. The company's software products include Global ECG Management System (GEMS), a software solution for cardiac event monitoring; GlobalCardio 12 Lead, a web enabled ECG device that is EMR compatible; and GEMS Lite for Windows, an electronic ECG receiving system. It also offers software modules, such as GEMS WIN Air, a live wireless ECG monitoring solution; AutoAttendant, which allows healthcare providers to focus on providing patient care; GEMS HL7 Interface that allows patient and follow-up information to be sent in an HL7 message format to other EMR systems that are HL7 compliant; and GlobalCardio EMR integration that enables bidirectional movement of data, including patient information, reports, and links. In addition, the company provides hardware products comprising HeartCheck PEN and HeartCheck, which are handheld ECG monitors; and Sirona telephonic and wireless event recorders, as well as HeartCheck CardiBeat. Further, it offers ASP services, including C4 ECG management services; and HeartCheck SMART Monitoring. Additionally, the company provides other products comprising GlobalCardio 3 Lead; ECG Viewer SDK; QRS Diagnostic; and QRS 12 Lead Universal products. CardioComm Solutions, Inc. was incorporated in 1989 and is headquartered in Toronto, Canada.

CEO
Mr. Etienne Grima CHE, MSc
Employee
0
Address
18 Wynford Drive
Toronto, M3C 3S2

CardioComm Solutions, Inc. Executives & BODs

CardioComm Solutions, Inc. Executives & BODs
# Name Age
1 Mr. Robert E. Caines
Chairman & Chief Financial Officer
70
2 Dr. Branislav Vasilijevic Ph.D.
Director of Software Engineering & Director
70
3 Mr. Etienne Grima CHE, MSc
Chief Executive Officer, Corporate Secretary & Director
70

CardioComm Solutions, Inc. Competitors